EGFR / c-MET
Ongoing clinical trials and approved products targeting EGFR / c-MET, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.
2ongoing therapy trials
0ongoing imaging trials
0approved products
Target note
- Full name
- EGFR and c-MET
- Nature
- Receptor tyrosine kinases (epidermal growth factor and hepatocyte growth factor).
- Normal expression
- Skin, liver, epithelia.
- Disease expression
- Lung, head and neck, colorectal and pancreatic cancers.
- Value
- The bispecific amivantamab, validated in lung cancer, serves as a vector to reach tumors co-expressing both receptors.
- Approaches
- Bispecific antibody labeled with ²²⁵Ac (FPI-2068), other labeled antibodies (FL-261).
- Indications explored
- Advanced solid tumors (phases 1-2).
- Points of caution
- Skin and liver expression: toxicities to monitor.
| Trial | Phase | Status | Sponsor | Countries |
|---|
| [225Ac]Ac-FL-261NCT07873450 · Colorectal | Phase 2 | Recruiting | Full-Life Technologies UK Limited | 1 |
| [225Ac]FPI-2068 (EGFR/c-MET)NCT06147037 · Small-cell lung cancer | Phase 1 | Active, not recruiting | AstraZeneca | 2 |
Cite this page
EGFR / c-MET. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/egfr-c-met/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.